Gastric transit and pharmacodynamics of a two-millimeter enteric-coated pancreatin microsphere preparation in patients with chronic pancreatitis.
It has been suggested that enteric-coated pancreatin microsphere (ECPM) preparations with sphere sizes larger than 1.7 mm pass through the stomach at a slower rate than a meal and therefore may be less efficacious in restoring pancreatic enzyme activity than preparations with smaller sphere sizes. The aim of this study was to investigate the gastric transit profile of a 2-mm ECPM preparation in relation to that of a solid meal and to simultaneously measure enzyme activities in eight patients with pancreatic exocrine insufficiency due to chronic pancreatitis. Gastric transit was assessed by double-isotope scintigraphy. A pancake was labeled with 99mTc. A 2-mm ECPM preparation was labeled with 171Er. Intraluminal pancreatic enzyme activities were assessed during a 6-hr period with the cholesteryl-[14C]octanoate breath test (for carboxyl ester lipase activity) and the N-benzoyl-L-tyrosyl-p-aminobenzoic acid/p-aminosalicylic acid (NBT-PABA/PAS) test (for chymotrypsin activity). The ECPM preparation passed through the stomach more rapidly (median 24 min) than the pancake (median 52 min, P < 0.05). During ECPM therapy, mean cumulative 14CO2 outputs rose significantly from 30% to 70% (P < 0.05), but remained below outcomes in healthy volunteers. Mean cumulative plasma PABA concentrations rose significantly from 46% to 87% (P < 0.05) and were not significantly different from outcomes in healthy volunteers. In chronic pancreatitis, a 2-mm ECPM preparation does not pass through the stomach more slowly than a solid meal, but in fact faster. Digestion of ester lipids and proteins showed an improvement to subnormal and normal levels, respectively.
Bruno
M J
MJ
Department of Nuclear Medicine, Academic Medical Center, Amsterdam, The Netherlands.
Borm
J J
JJ
Hoek
F J
FJ
Delzenne
B
B
Hofmann
A F
AF
de Goeij
J J
JJ
van Royen
E A
EA
van Leeuwen
D J
DJ
Tytgat
G N
GN
D010129:4-Aminobenzoic Acid / Q000097:blood; D000328:Adult; D000368:Aged; D001944:Breath Tests; D002788:Cholesterol Esters / Q000032:analysis; D002908:Chronic Disease; D005260:Female; D005753:Gastric Mucosa / Q000378:metabolism*; D005765:Gastrointestinal Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D005772:Gastrointestinal Transit; D006801:Humans; D008297:Male; D008863:Microspheres; D008875:Middle Aged; D010194:Pancreatin / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D010195:Pancreatitis / Q000201:enzymology / Q000378:metabolism*; D013608:Tablets, Enteric-Coated; D013667:Technetium
D002788:Cholesterol Esters; D005765:Gastrointestinal Agents; D013608:Tablets, Enteric-Coated; C053743:cholesteryl octanoate; D013667:Technetium; D010194:Pancreatin; D010129:4-Aminobenzoic Acid